Neuren Pharmaceuticals (ASX:NEU) Reports Q2 2025 DAYBUE Sales Growth
Neuren Pharmaceuticals (ASX:NEU) reports a 14% increase in DAYBUE Q2 2025 sales, reaching US$96.1 million.
Category: ASX-NEU
Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans
Neuren Pharmaceuticals (ASX:NEU) reports a record A$166m income in 2024, driven by DAYBUE sales and initiates Phase 3 trials for NNZ-2591.